7 results about "Immunoglobulin domain" patented technology

Provided are bispecific antibodies comprising first and second VIIII binding domains that specifically bind to the extracellular domains of interleukin- 10 receptor (IL-10R) alpha subunit (IL-10Rα) and beta subunit (IL-10Rβ), and that selectively suppress activation of myeloid cells and induce minimal or no direct activation of T cells or B cells.

The present disclosure provides a method for degrading a target protein, comprising: contacting an IL-2Rβγ positive cell with a multispecific binding protein, wherein the multispecific binding protein comprises: a) a first cell surface binding moiety that specifically binds to a CD122 (IL-2Rβ) subunit and / or a CD132 (IL-2Rγ) subunit, on the surface of the IL-2Rβγ positive cell, wherein the first cell surface binding moiety comprises at least one immunoglobulin domain or a fragment thereof; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein specific binding of the multispecific binding protein to the IL-2Rβ subunit and / or the IL-2Rγ subunit facilitates the internalization of the target protein into the IL-2Rβγ positive cell. The present disclosure also provides multispecific binding proteins and methods of using the multispecific binding proteins to treat disease.

The present invention is based on the finding that administration of a polypeptide comprising at least one immunoglobulin single variable domain against vWF to human TTP patients provides a significantly reduced time to response. The present invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) directed against von Willebrand factor (vWF) for use in treating vWF-associated diseases in a human in need thereof. The present invention further relates to dosage unit forms, kits, and medical uses for treating TTP.

This technology aims to provide a novel type of drug for treating patients suffering from cancer. [Solution] Specifically, this technology provides a polypeptide comprising at least four immunoglobulin monovariable domains (ISVDs), characterized in that one ISVD binds to the TCR and at least two ISVDs bind to GPC3. This technology also provides nucleic acids, vectors, and compositions.

The present disclosure is directed to methods for preventing or treating helminth (e.g., filarial) diseases in animals. The methods are accomplished by administering to the animal a therapeutically effective amount of an inhibitor of UDP-glucoronosyl transferase (UGT) or immunoglobulin I-set domain containing protein (Igl-DCP, also known as BMA-Lad-2). The inhibitors include those known to inhibit glucuronyltransferase enzyme activity as well as cell adhesion molecule inhibitors and antibodies specific for Igl-DCP and / or UGT.

Provided are an Irisin fusion protein, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a cell and applications thereof. Specifically, provided is a fusion protein comprising an Irisin polypeptide and an immunoglobulin Fc domain, wherein the Irisin polypeptide is covalently linked to the immunoglobulin Fc domain via a linker comprising an enzyme recognition sequence. Also provided are a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a cell and a composition thereof, and use of the fusion protein, the polynucleotide, the vector, the cell and the composition in medicine and / or in the preparation of a medicament for treating or preventing metabolic diseases, complications or other related diseases associated with disorders of glucose metabolism and / or lipid metabolism.